FDA Working On “Modern” Regulatory Approach Through Collaborations
Executive Summary
FDA must modernize its regulatory tools under the Critical Path Initiative to keep parity with advances in drug development, FDA Deputy Commissioner for Medical and Scientific Affairs Scott Gottlieb said at the Pharmaceutical Compliance Congress & Best Practices Forum Nov. 7-9
You may also be interested in...
FDA Wants Cardiovascular Adverse Event Data Broadly Available For Research
FDA outlined two proposals to better monitor cardiovascular adverse events, mainly focusing on means to create more comprehensive links between physicians, industry and academia, at a recent Drug Information Association conference
FDA Wants Cardiovascular Adverse Event Data Broadly Available For Research
FDA outlined two proposals to better monitor cardiovascular adverse events, mainly focusing on means to create more comprehensive links between physicians, industry and academia, at a recent Drug Information Association conference
FDA Can Expand Access To Experimental Drugs, Without Compromising Trials
FDA would be able to maintain the integrity of rigorous clinical trials and permit increased access to experimental drugs through the use of better science, according to former FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb